Fortress Biotech Inc (NAS:FBIO)
$ 1.7 0.03 (1.8%) Market Cap: 32.70 Mil Enterprise Value: 35.86 Mil PE Ratio: 0 PB Ratio: 1.14 GF Score: 50/100

Fortress Biotech Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 20, 2021 / 06:55PM GMT
Release Date Price: $47.4 (-5.67%)
Leland Gershell
Oppenheimer & Co. Inc. - Analyst

Good afternoon, everyone. Welcome to our first afternoon here at Oppenheimer's Virtual Fall Healthcare Life Sciences and MedTech Summit. We are very happy to have with us for this session Fortress Biotech.

Fortress is developing a variety of candidates in different therapeutic areas and different stages of clinical trials and also maintains stakes in other innovative companies. We have Lindsay Rosenwald, who is the Company's Chairman and CEO, as well as Bill Begien on the IR team. (Operator Instructions). With that, I'll turn the podium over to Lindsay.

Lindsay Rosenwald
Fortress Biotech, Inc. - Chairman, President & CEO

Thanks, Leland. Thanks so much to the Oppenheimer team for the opportunity to present today. And obviously also thanks to everybody who is watching this presentation. First, I will be making some forward-looking statements. Feel free to look at our SEC filings for all our risk factors and complete financials.

This is a snapshot of what we have going on at Fortress

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot